PSTV (Plus Therapeutics) Tariff Resilience Score: 5/10 (As of Jun. 29, 2026)


PSTV Plus Therapeutics Inc PSTV
26 GF Score
Price $4.29
! 2 Warning Signs
View Full Analysis

What is Plus Therapeutics Tariff Resilience Score?

Plus Therapeutics PSTV +1.42% 26 Tariff Resilience Score is 5 as of Jun. 29, 2026. GuruFocus rates PSTV with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,375 Biotechnology companies, Plus Therapeutics ranks better than 62.25% on this metric.

Plus Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Plus Therapeutics has Plus Therapeutics relies on global suppliers for raw materials. While it has some pricing power, its niche market limits flexibility. Previous tariffs have impacted costs, but mitigation strategies are in place.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Plus Therapeutics might have Average Resilient.

Plus Therapeutics  (NAS:PSTV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Plus Therapeutics Tariff Resilience Score Related Terms

PSTV vs KYNB, VTGN, TVGN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Plus Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Plus Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Tariff Resilience Score falls into.


PSTV
26GF Score
Plus Therapeutics Inc PSTV
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Plus Therapeutics (PSTV) has a Tariff Resilience Score of 5 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Plus Therapeutics ranks #519 out of 1375 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Plus Therapeutics' Tariff Resilience Score too high?
Plus Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Plus Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Plus Therapeutics ranks #519 out of 1375 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Plus Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' Tariff Resilience Score compare to KYNB and VTGN?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #519 out of 1375 companies for Tariff Resilience Score. This puts Plus Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Plus Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Plus Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Plus Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Plus Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current Tariff Resilience Score is 5 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Plus Therapeutics Business Description

Other Exchanges XMP1:Germany
Address 6420 Levit Green Boulevard, Suite 210, Houston, TX, USA, 77021
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
26GF Score

Get the complete analysis for PSTV

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.29
Price